S

Sonnet BioTherapeutics Holdings
D

SONN

1.17000
USD
0.02
(1.74%)
مغلق
حجم التداول
178
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
3,703,998
أصول ذات صلة
ENPH
ENPH
0.320
(0.70%)
45.930 USD
L
LITE
3.270
(3.97%)
85.700 USD
ON
ON
2.860
(5.60%)
53.890 USD
S
SEDG
0.690
(2.96%)
23.990 USD
TER
TER
4.600
(5.54%)
87.700 USD
V
VUZI
0.21000
(7.13%)
3.15500 USD
المزيد
الأخبار المقالات

العنوان: Sonnet BioTherapeutics Holdings Inc

القطاع: Healthcare
الصناعة: Biotechnology
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.